| Primary information |
|---|
| ID | antitb_1316, |
| Name | 20858205 |
| N-Terminal modification | L-LL37 |
| C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 31 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = Ie μg/mL(inactive) |
| Inhibition Concentration | In vitro |
| Sequence | 2011 |
| Cytotoxicity | Human erythrocyte |
| In vivo Model | NA |
| Lethal Dose | HC50 = 43.5 μg/mL |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1317, |
| Name | 20858205 |
| N-Terminal modification | D-LL37 |
| C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 31 |
| Source | D |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 200 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2011 |
| Cytotoxicity | Human erythrocyte |
| In vivo Model | NA |
| Lethal Dose | HC50 = 125 μg/mL |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |